Celgene (CELG) adds $3.34 to $66.29 after RBC upgraded the stock to Outperform from Sector Perform. The firm cites product pipeline, earnings growth, and valuations for the upgrade. Shares are rallying and options volume in the biotech is 6,260 calls/180 puts. Most of the action has been in smaller sizes. The top trade is a 287-lot of Oct 65 calls on the 94-cent bid. Oct 67.5 calls, which are 1.8 percent OTM and expire in 11 days, are the most actives. 2,657 traded (51 percent Ask). Nov 67.5, Oct 70, and Nov 65 calls are seeing interest as well. Implied volatility is up 3 percent, but at relatively low levels of only 33 percent. The stock has performed well lately, up 27.9 percent over the past two months and touching new 52-week highs near $67 today.